Table 1.
Number in Figure 4 | Therapy | Therapy approach | Stage | Clinical trial identifier | Reference |
---|---|---|---|---|---|
1, 2 | Imiquimod + poly(I:C) | TLR7 agonist + TLR3 agonist | In vitro/in vivo | — | Klein et al. [35] |
| |||||
2 | Poly(I:C) | TLR3 agonist + tremelimumab + durvalumab | Phase I/II | NCT02643303 | No study was reported yet. |
| |||||
3 | VTX-2337 | TLR8 agonist | Phase I | NCT00688415 | Dietsch et al. [37] |
TLR8 agonist + cetuximab | Phase I/II | NCT01334177 | Stephenson et al. (2013) and Chow et al. [36] | ||
TLR8 agonist + cisplatin or +carboplatin/fluorouracil/cetuximab | Phase II | NCT01836029 | No study was reported yet. | ||
| |||||
4 | OK-432 (Picibanil) | TLR4 agonist | Phase I | NCT01149902 | Galluzzi et al. [30] |
| |||||
5 | ISA201 | TLR2 agonist + 2 HPV16 E6 peptides | Phase I | NCT02821494 | Bann et al. [38] |
| |||||
6 | EMD 1201081 | TLR9 agonist which was tested with cetuximab | Phase II | NCT01040832 | Ruzsa et al. [39] |
TLR9 agonist + fluorouracil + cisplatin + cetuximab | Phase I | NCT01360827 | No study was reported yet. | ||
| |||||
7 | CBLB502 (entolimod) | TLR5 agonist | Phase I | NCT01728480 | Toshkov et al. [40] |